BioPharmSignal logoBioPharmSignal

Biotech News

AngioDynamics Announces Publication of DIRECT Study Results and New Category I CPT Code for Pancreatic IRE

AngioDynamics (ANGO)AngioDynamicsFDA / regulatory

Prospective, multicenter FDA IDE study found an IRE-based treatment strategy was associated with longer overall survival in Stage III pancreatic cancer; new Category I CPT code for open pancreatic IRE takes effect January 1, 2027 LATHAM, N.Y. --(BUSINESS WIRE)--Oct. 21, 2026-- AngioDynamics, Inc.

Related news

ANGOAngioDynamics2026-10-14 11:00 EST

AngioDynamics Announces Humana Medicare Advantage Coverage Policy Supporting Broader Access to NanoKnife® IRE for Prostate and Liver Cancer

RVMDRevolution Medicines2026-09-14 20:05 EST

Revolution Medicines Announces U.S. FDA Breakthrough Therapy Designation for RASONQUE™ (daraxonrasib) in Combination with Chemotherapy for First Line Metastatic Pancreatic Cancer

RVMDRevolution Medicines2026-08-26 16:59 EST

U.S. FDA Approves Revolution Medicines’ RASONQUE™ (daraxonrasib), the First Broad RAS-Targeted Medicine in Metastatic Pancreatic Cancer

ANGOAngioDynamics2026-10-08 10:02 EST

AngioDynamics Reports Fiscal Year 2027 First Quarter Financial Results; Continued Execution Drives Med Tech Growth and Profitability

IDYAIDEAYA Biosciences2026-08-31 10:00 EST

IDEAYA Biosciences Announces Successful FDA Type C Meeting for IDE849, DLL3 TOP1 ADC, on Phase 3 Registrational Trial Design for Potential Accelerated and Full Approval in Extensive Stage Small Cell Lung Cancer

REGNRegeneron Pharmaceuticals2026-08-19 17:58 EST

Pasatru™ (garetosmab-grts) First and Only FDA-approved Treatment Demonstrating Reduction in New Heterotopic Ossification (HO) Lesions and Clinician-Assessed Flare-ups in a Placebo-controlled Trial in Adults with Fibrodysplasia Ossificans Progressiva (FOP)

LEGNLegend Biotech Corporation2026-10-15 12:00 EST

Legend Biotech Announces U.S. FDA Clearance of IND Application for LB2501, an Investigational CD19/CD20 In Vivo CAR-T Therapy

JNJJohnson & Johnson2026-09-21 14:33 EST

European Commission approval of ICOTYDE™▼(icotrokinra) ushers in new era for first-line systemic treatment of plaque psoriasis with a targeted oral peptide

TEVATeva Pharmaceutical Industries2026-08-19 12:30 EST

U.S. FDA Accepts Teva’s New Drug Application (NDA) and Grants Priority Review for Ecopipam, a First-in-Class Investigational Therapy for Pediatric Patients with Tourette Syndrome

GSKGSK plc2026-10-20 17:42 EST

Hibsago (bepirovirsen) approved in the US for the treatment of chronic hepatitis B (CHB)

View all latest news

AngioDynamics

Vascular and Interventional Technology AngioDynamics develops medical technologies that restore blood flow, remove thrombus and treat selected tumors. Its portfolio is organized around higher-growth interventional platforms and a broader medical-device business. Mechanical Thrombectomy AlphaVac and AngioVac are mechanical aspiration...

Recent company news

ANGOAngioDynamics2026-10-21 12:30 EST

AngioDynamics Announces Publication of DIRECT Study Results and New Category I CPT Code for Pancreatic IRE

ANGOAngioDynamics2026-10-14 11:00 EST

AngioDynamics Announces Humana Medicare Advantage Coverage Policy Supporting Broader Access to NanoKnife® IRE for Prostate and Liver Cancer

ANGOAngioDynamics2026-10-08 10:02 EST

AngioDynamics Reports Fiscal Year 2027 First Quarter Financial Results; Continued Execution Drives Med Tech Growth and Profitability

ANGOAngioDynamics2026-10-08 10:00 EST

AngioDynamics Announces Appointment of Eric Honroth as President and Chief Executive Officer

ANGOAngioDynamics2026-10-02 10:00 EST

AngioDynamics and The PERT Consortium® Name Jacobi Hospital as ALPHA-PE Research Fund Award Recipient to Advance Real-World Pulmonary Embolism Evidence

Stock data

Close
11.81 USD
Market cap
453.68M USD
Exchange
NASDAQ
Sector
MedTech
Location
United States